

## Credit Rating Company Moody's Changes Monsanto's Investor Rating to "Negative"

By Christina Sarich

Global Research, May 11, 2015

Natural Society

Theme: Global Economy

Approximately \$8 billion in debt securities are affecting a popular investor's service decision about one of biotech's biggest. Investing credit rating company Moody's has affirmed that Monsanto's new rating is being downgraded from 'neutral' to 'negative' following Syngenta's announcement that it has refused Monsanto's unsolicited bid of CHF449 per Syngenta share in a combination of cash and stock.

Monsanto's offer would have valued another biotech bully at a mere US\$20 billion paid in cash. For investors in Monsanto, Moody's <u>calls their</u> aggressive attempt at takeover a "heightened event risk" due to their more aggressive financial policy.

Indeed – Monsanto's financial policy seems to match their aggressive actions elsewhere – from bullying federal judges to trying to orchestrate a trade monopoly through the <u>Trans</u> <u>Pacific Partnership (TPP)</u>.

Moody's also doesn't seem to feel confident that Monsanto could come up with the cash even if Syngenta had accepted their deal. John Rogers, Senior Vice President at Moody's said:

"Monsanto's bid is indicative of a more aggressive financial policy, especially after it has levered up to undertake a sizable share repurchase program over the past 10 months."

As per Moody's ratings rationale, the A3 long-term debt and Prime-2 commercial paper ratings reflect Monsanto's leadership position in genetically modified (GM) and hybrid seeds, modest leverage (1.6x Net Debt/EBITDA, Retained Cash Flow/Net Debt of 45%), and excellent liquidity.

However, Moody's doesn't seem to take into account the fact that consumers and farmers are more increasingly refusing GM products – whether it's the glyphosate that Monsanto sells via Round Up or the Round Up Ready crops they push on farmers throughout the world.

There have been increasing farmer uprisings against Monsanto, and the <u>demand for organic is booming</u> so much that the US is now importing more organic food than they are growing. This doesn't bode well for a company that makes its cash by lying, stealing, and poisoning.

Moody's also bases its assessment on standard adjustments to Monsanto's financial statements (which currently show debt at \$1.8 billion – \$1.6 billion in operating leases, and \$200 million in pensions for their employees).

Furthermore, Moody's states "Monsanto's market position is supported by the largest germplasm library in the industry, technology licensing agreements with its main competitors and clearly defined research pipeline."

It doesn't mention that Monsanto's research pipeline is all paid for and that the company has an entire department dedicated to <u>discounting any scientific research</u> which paints them in an unfavorable light. This is obviously not a sustainable way to do business, since even the World Health Organization has called glyphosate '<u>probably carcinogenic</u>' and organizations everywhere are now demanding a ban on glyphosate.

We can only hope that the Monsanto/Syngenta merger does not happen. It would result in a bloated agricultural chemical giant capable of dominating the seed market at almost three times the rate of its nearest competitor.

Follow us: <u>@naturalsociety on Twitter</u> | <u>NaturalSociety on Facebook</u>

The original source of this article is <u>Natural Society</u> Copyright © <u>Christina Sarich</u>, <u>Natural Society</u>, 2015

## **Comment on Global Research Articles on our Facebook page**

## **Become a Member of Global Research**

Articles by: Christina Sarich

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>